摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7,8-dihydro-6H-dipyrido[1,2-a;2',1'-c][1,4]diazepinium | 7325-63-5

中文名称
——
中文别名
——
英文名称
7,8-dihydro-6H-dipyrido[1,2-a;2',1'-c][1,4]diazepinium
英文别名
propyldiquat dication;viologen-550 dication;N,N'-Trimethylen-2,2'-dipyridylium;7,8-Dihydro-6H-dipyrido<1,2a-2,1c>-<1,4>-diazepinium;1,1'-Trimethylen-dipyridylium-(2,2');1,1'-Trimethylen-2,2'-bipyridylium;1,1'-Propylen-2,2'-bipyridinium;6H-Dipyrido(1,2-a:2',1'-c)(1,4)diazepinediium, 7,8-dihydro-;7,11-diazoniatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaene
7,8-dihydro-6H-dipyrido[1,2-a;2',1'-c][1,4]diazepinium化学式
CAS
7325-63-5
化学式
C13H14N2
mdl
——
分子量
198.268
InChiKey
YNDLPPBMXQTSDS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    7.8
  • 氢给体数:
    0
  • 氢受体数:
    0

反应信息

  • 作为反应物:
    描述:
    7,8-dihydro-6H-dipyrido[1,2-a;2',1'-c][1,4]diazepinium三丁基膦 作用下, 以 甲醇乙腈 为溶剂, 生成 propyldiquat cation
    参考文献:
    名称:
    紫精受体结构变化对三丁基膦单电子转移速率的影响。
    摘要:
    在氩气气氛下,在含有大量甲醇的乙腈中,用三丁基膦(1)处理2,2'-联吡啶和1,10-菲咯啉的“柔性” 3和“刚性”环状紫精4。 。从后者到前者很容易发生单电子转移(SET),SET到4的速度是SET到3的10(5)-10(6)倍。认为后者的重组能λ比前一个SET大,因为3在单电子还原成其自由基阳离子时发生结构变化,而4的单电子还原发生时没有结构变化。考虑到lambda的差异,
    DOI:
    10.1039/b605362a
  • 作为产物:
    描述:
    2,2'-联吡啶 、 alkaline earth salt of/the/ methylsulfuric acid 以 乙腈 为溶剂, 生成 7,8-dihydro-6H-dipyrido[1,2-a;2',1'-c][1,4]diazepinium
    参考文献:
    名称:
    紫精受体结构变化对三丁基膦单电子转移速率的影响。
    摘要:
    在氩气气氛下,在含有大量甲醇的乙腈中,用三丁基膦(1)处理2,2'-联吡啶和1,10-菲咯啉的“柔性” 3和“刚性”环状紫精4。 。从后者到前者很容易发生单电子转移(SET),SET到4的速度是SET到3的10(5)-10(6)倍。认为后者的重组能λ比前一个SET大,因为3在单电子还原成其自由基阳离子时发生结构变化,而4的单电子还原发生时没有结构变化。考虑到lambda的差异,
    DOI:
    10.1039/b605362a
点击查看最新优质反应信息

文献信息

  • Optimizing electron transfer from CdSe QDs to hydrogenase for photocatalytic H<sub>2</sub> production
    作者:Monica L. K. Sanchez、Chang-Hao Wu、Michael W. W. Adams、R. Brian Dyer
    DOI:10.1039/c9cc01150a
    日期:——
    A series of viologen related redox mediators of varying reduction potential has been characterized and their utility as electron shuttles between CdSe quantum dots and hydrogenase enzyme has been demonstrated. Tuning the mediator LUMO energy optimizes the performance of this hybrid photocatalytic system by balancing electron transfer rates of the shuttle.
    表征了一系列具有不同还原电位的与紫精相关的氧化还原介体,并证明了它们作为CdSe量子点和氢化酶之间的电子穿梭物的效用。调节介体LUMO能量可通过平衡梭的电子传递速率来优化此混合光催化系统的性能。
  • Lewis, Zeitschrift fur Physikalische Chemie, 1999, vol. 212, # 2, p. 161 - 172
    作者:Lewis
    DOI:——
    日期:——
  • Equilibrium between 2-oxomorpholin-3-yl radicals and viologen radicals. Determination of reduction potentials
    作者:Robert Patrick Mahoney、Paul A. Fretwell、Samuel H. Demirdji、R. L. Mauldin、Olester Benson、Tad H. Koch
    DOI:10.1021/ja00027a026
    日期:1992.1
    Bi(3,5,5-trimethyl-2-oxomorpholin-3-yl) (TM-3 dimer) undergoes bond homolysis to yield 3,5,5-trimethyl-2-oxomorpholin-3-yl (TM-3), which reduces propyldiquat (PDQ2+) to its radical cation PDQ+. The byproduct is 5,6-dihydro-3, 5,5-trimethyl-1,4-oxazin-2-one (8). Similarly, bi(5,5-dimethyl-4-ethyl-2-oxomorpholin-3-yl) (DEM-3 dimer) cleaves to 5,5-dimethyl-4-ethyl-2-oxomorpholin-3-yl (DEM-3), which reduces paraquat (PQ2+) to its radical cation PQ+. The byproduct, 5,5-dimethyl-4-ethyl-3-methoxy-2-oxomorpholine (10), results from rapid addition of methanol solvent to the transient 5,6-dihydro-4-ethyl-5, 5-dimethyl-1,4-oxazin-2-onium cation (11). Concentration versus time data for the respective viologen radical cations together with reduction potentials for the viologens place the reduction potentials for TM-3 dimer and DEM-3 dimer at -0.56 and -0.33 V versus NHE, respectively, in Tris/Tris-H+ buffered methanol. The kinetics of reduction are analyzed using numerical integration, and the two reducing agents are compared with dithionite.
  • ORGANIC COMPOUND, ELECTROCHROMIC DEVICE, ELECTROCHROMIC APPARATUS, OPTICAL FILTER, IMAGE PICKUP APPARATUS, LENS UNIT, AND WINDOW MEMBER
    申请人:CANON KABUSHIKI KAISHA
    公开号:US20190002758A1
    公开(公告)日:2019-01-03
    An organic compound is represented by general formula (1) below: where X 1 and X 2 are each independently selected from the group consisting of an alkyl group, an aryl group, and an aralkyl group; R 11 to R 16 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, an aryl group, a heterocyclic group, and a halogen atom; R 21 and R 22 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an aryl group, and an aralkyl group; and A 1 − and A 2 − each independently represent a monovalent anion.
  • [EN] COMPLEX COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING SAME<br/>[FR] COMPOSÉ COMPLEXE ET SUPPORT D'ENREGISTREMENT OPTIQUE LE CONTENANT
    申请人:KH NEOCHEM CO LTD
    公开号:WO2013069545A1
    公开(公告)日:2013-05-16
    式(I)(式中、R1、R2、R3およびR4は、同一または異なって、水素原子、置換基を有していてもよいアミノ基、置換基を有していてもよいアルコキシル基等を表し、R5は水素原子等を表し、環Aは置換基を有していてもよい複素環を表し、該複素環は、テトラゾール環等からなる群より選ばれる)で表される化合物と、金属と、アミンに1つ以上のプロトンが付加することにより生じるイオン、アンモニウムイオンおよび第4級アンモニウムイオンからなる群から選ばれる1種と、からなる、優れた記録再生特性等を有する光記録媒体に用いられる錯化合物を提供する。
查看更多

同类化合物

氯吡卓醇 利喷西平 丙吡西平 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]苯甲酰胺 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]乙酰胺 9-叠氮基-11-乙基-6-甲基吡啶并[3,2-c][1,5]苯并二氮杂卓-5-酮 5-甲基-11-(甲磺酰)-5,11-二氢-6H-二吡啶并[3,2-b:2',3'-e][1,4]重氮基庚英-6-酮 5,11-二氢-4-甲基-6H-二吡啶并[3,2-b:2',3'-e][1,4]二氮杂卓-6-酮 4-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 4-苯基-1,3,4,5-四氢-2H-吡啶并[2,3-b][1,4]二氮杂卓-2-硫酮 4-(吗啉-4-基甲基)-1H-吡啶并[2,3-e][1,4]二氮杂卓-2,3,5(4H)-三酮 4,5-二氢-1H-吡啶并[2,3-E][1,4]重氮基庚英-3(2H)-酮 3-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 3-(乙酰氧基)-7-氯-5-(2-氯苯基)-1,3-二氢-2H-吡啶并[3,2-e]-1,4-二氮杂卓-2-酮 3,4,6,7-四氢-10-氯-1-苯基-8H-吡啶并[3,2,1-jk][1,4]苯并二氮杂卓-4,8-二酮 2-甲基-5-(2-吗啉-4-基乙基)-3,5-二氢-4H-吡啶并[2,3-b][1,4]重氮基庚英-4-酮盐酸 1OH-吡啶并(3,2-d)噻吩并(3,2-e)(1,4)-重氮基庚英-10-酮,4,9-二氢-4-((4-甲基-1-哌嗪基)乙酰基)-,盐酸盐 11-(N-甲基六氢烟酰基)-6,11-二氢-5H-吡啶并(2,3-b)-1,5-苯并二氮杂卓-5-酮 1-(5-甲基-3,4-二氢-2H-吡啶并[2,3-B] [1,4]二氮杂-1-基)乙酮 7,7a,8,9-tetrahydro-5-methyl-5H-pyrido<2,3-b>pyrrole<1,2-d><1,4>diazepin-6,10-dione 2-(3-butoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone (S,E)-N-methyl-3-(2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-((3-methylbenzofuran-2-yl)methyl)acrylamide trifluoroacetic acid salt 4-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-d][1,3]diazepin-8-yloxy)butyl methanesulfonate 8-p-tolyl-6,7,9,14,15,16-hexahydroquinoxalino[1,2-a]pyrrolo[2,3-b][1,5]pyridodiazepin-6,7,15-trione 2-(2-furyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methylphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-phenyl-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(2-thienyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-bromophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-fluorophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(4-fluorophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(1-naphthyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(2-furyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(4-bromophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(2-thienyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 8-chloro-1-methyl-1,2,3,4-tetrahydro-5H-pyrido[2,3-e][1,4]diazepin-5-one 2,3-dihydro-3-hydroxyimino-1-methyl-5-phenyl-1H-pyrido[4,3-e]-1,4-diazepine-2-one 7a,8,9,10-tetrahydro-5-methyldipyrido<2,3-b:1,2-d><1,4>diazepin-6,11(5H,7H)-dione 1-phenyl-2-{(Z)-(4RS)-4-(3-bromo-4,5-dimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrido[2,3-b][1,4]diazepin-2-ylidene}-ethanone (+/-)-(R,R)-2-chloro-5-methyl-1,6a,7,8,9,10,10a,11-octahydrobenzo[b]pyrido[2,3-e][1,4]diazepin-4-one (E)-N-methyl-N-((3-methylbenzo[b]thiophen-2-yl)methyl)-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide 2-(3-Methoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone 8-Bromo-1,3-dihydro-4,9-dimethyl-2H-pyrido[2,3-b][1,4]diazepin-2-one 5,13-Dimethyl-7,11-diazoniatricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaene 5-(2-Morpholin-4-yl-ethyl)-2-phenyl-3,5-dihydro-pyrido[3,4-b][1,4]diazepin-4-one 4,9-dihydro-10H-pyrido[3,2-b]thieno[3,2-e][1,4]-diazepin-10-one (10S)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one (10R)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one